Top

The European Journal of Health Economics

Published in:

01-12-2003 | Original Papers

Project of Polish guidelines for conducting pharmacoeconomic evaluations in comparison to international health economic guidelines

Authors: Ewa Orlewska, Piotr Mierzejewski

Published in: The European Journal of Health Economics | Issue 4/2003

Abstract

We present the project of Polish guidelines for conducting economic evaluation and compare them with international health economic guidelines, highlighting areas of agreement and dissent. The Polish guidelines are very similar to those in Australia, Canada, and some European Union countries. Nevertheless a number of implementation and attitude problems seem to have delayed the introduction of pharmacoeconomic evaluation as a prerequisite for reimbursement of new pharmaceutical products. A transitional phase is required for collecting reliable cost data and familiarizing and training personnel both in public authorities and private industry

Laupacis A, Fenny D, Detsky AS, Tugwell PX (1992) How attractive does a new technology have to be to warrant adaptation and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J 146:473–481PubMed

Winkelmayer WC, Weinstein MC, Mittleman MA, et al (2002) Health economic evaluations: the special case of end-stage renal disease treatment. Med Decis Making 22:417–430PubMed

Orlewska E (2000) Analiza koszty-efektywność stosowania preparatu Arthrotec 75 vs diklofenak SR 75 u chorych z reumatoidalnym zapaleniem stawów lub chorobą zwyrodnieniową stawów w Polsce (The cost-effectiveness of Arthrotec 75 vs. diclofenac SR 75 in the treatment of rheumatoid arthritis and osteoarthritis in Poland). Farmakoekonomika 1:2–18

Hutton J, Mauskopf J, Benedict A (2002) Is it worth it? Problems in creating a cost-effectiveness threshold for decision-making. Presented at ISPOR 5th Annual European Congress, 3–5 November, Rotterdam, The Netherlands

Anonymous (2002) Statistical yearbook of Republic of Poland. Warsaw, Poland

Orlewska E (1999) Wytyczne dla "dobrej praktyki farmakoekonomicznej" (Guidelines for good pharmacoeconomical practice). Zdrowie i Zarządzanie 1:16–26

Orlewska E (1999) Czy wytyczne są potrzebne? (Are the guidelines needed?). In: Podstawy farmakoekonomiki (Principles in pharmacoeconomics). Unimed: Warsaw

Orlewska E, Mierzejewski P (2000) Polish guidelines for conducting pharmacoeconomic evaluations (project). Farmakoekonomika [Suppl 1]:12–20

10.

Orlewska E, Mierzejewski P (2000) Polskie wytyczne przeprowadzania badań farmakoekonomicznych (projekt) (Polish guidelines for conducting pharmacoeconomic evaluations (project). Presented at the conference "Zagadnienia farmakoekonomiki" (Issues in Pharmacoeconomics) organized by the Polish Society of Clinical Pharmacology and Therapy and Polish Society of Pharmacoeconomics, 12 December 12, Poznań, Poland

11.

Orlewska E, Mierzejewski P (2002) Wytyczne dobrej praktyki farmakoekonomicznej (Guidelines for good pharmacoeconomical practice). Presented at the conference organized by National Union of Sickness Funds, 9–10 November, Osuchów, Poland

12.

Orlewska E, Mierzejewski P (2001) Polskie wytyczne przeprowadzania badań farmakoekonomicznych (projekt) (Polish guidelines for conducting pharmacoeconomic evaluations (project). Presented at VI Polish Conference Quality in Healthcare, Standaryzacja w systemie opieki zdrowotnej (Standardisation in the healthcare system), 25–27 April, Cracow, Poland

13.

Orlewska E, Mierzejewski P (2001) Polish guidelines for conducting pharmacoeconomic evaluations in comparison to international health economic guidelines (abstract). Value Health 4:170

14.

Orlewska E, Mierzejewski P (2002) Polish guidelines for conducting financial analysis–project. Farmakoekonomika [Suppl 1]:6–8

15.

Trueman P, Drummond M, Hutton J (2001) Developing guidance for budget impact analysis. Pharmacoeconomics 19:609–621PubMed

16.

Orlewska E, Mierzejewski P (2003) Polish guidelines for costing: methods and standard costs for pharmacoeconomic evaluation (project). Farmakoekonomika 1:2–8

17.

Gold RG, Russell LR, Siegel JE, et al (1996) Cost-effectiveness in health and medicine. Oxford University Press: New York

18.

Drummond MF, O'Brien B, Stoddart LG, et al (1997) Methods for economic evaluation of health care programmes, 2nd edn. Oxford University Press: Oxford

19.

Orlewska E (1999) Podstawy Farmakoekonomiki (Principles in Pharmacoeconomics). Unimed: Warsaw

20.

Drummond MF (1994) Guidelines for pharmacoeconomic studies—the ways forward. Pharmacoeconomics 6:493–497PubMed

21.

Hjelmgren J, Berggren F, Andersson F (2001) Health economic guidelines—similarities, differences and some implications. Value Health 4:225–250CrossRefPubMed

22.

Commonwealth Department of Human Services and Health (1995) Guidelines for the pharmaceutical industry on preparation of submissions to the Pharmaceutical Benefits Advisory Committee. Australian Government Publishing Service: Canberra

23.

Ontario Ministry of Health (1994) Ontario Guidelines for economic analysis of pharmaceutical products. Ontario Ministry of Health: Toronto

24.

Finish Ministry of Social Affairs and Health (1999) Guidelines for preparation of an account of health economic aspects. Finish Ministry of Social Affairs and Health: Helsinki

25.

Riteco JA, de Heij LJM, van Luijn JCF et al (1999) Dutch guidelines for pharmacoeconomic research. College Voor Zorgverzekeringen: Amstelveen

26.

Portuguese Pharmacy and Medicines Institute (1998) Orientacoes metodologicas para estudos de avaliacao economica de medicamentos. INFARMED: Portugal

27.

National Institute for Clinical Excellence (2001) Revised guidelines for manufacturers, sponsors of technologies making submissions to the Institute. National Institute for Clinical Excellence: London. http://www.nice.org.uk

28.

Regence BlueShield (1997) Guidelines for the submission of clinical and economic data supporting formulary consideration. Regence Washington Health–University of Washington: Seattle

29.

Commonwealth Department of Health, Housing, Local Government and Community Services (1993) Manual of resource items and their associated costs. Commonwealth Department of Health, Housing, Local Government and Community Services: Canberra

30.

Baladi JF (1996) A guidance document for the costing process. Canadian Coordinating Office for Health Technology Assessment: Ottawa

31.

Oostenbrick JB, Koopmanschap MA, Rutten FFH (2000) Manual for costing: methods and standard costs for economic evaluations in health care. College voor Zorgverzekerinen: Amstelveen

Title: Project of Polish guidelines for conducting pharmacoeconomic evaluations in comparison to international health economic guidelines
Authors: Ewa Orlewska
Piotr Mierzejewski
Publication date: 01-12-2003
Publisher: Springer-Verlag
Published in: The European Journal of Health Economics / Issue 4/2003
Print ISSN: 1618-7598
Electronic ISSN: 1618-7601
DOI: https://doi.org/10.1007/s10198-003-0185-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Project of Polish guidelines for conducting pharmacoeconomic evaluations in comparison to international health economic guidelines

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2003

Testing assumptions of quality-adjusted life-year calculations

Cost-effectiveness of fondaparinux vs. enoxaparin as venous thromboembolism prophylaxis in Sweden

The lag between effectiveness and cost-effectiveness evidence of new drugs

An exponential representation of health state utility

An overview of the Greek pharmaceutical market

Economic burden of obesity and its complications in Germany